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Abstract Pulmonary arterial hypertension (PAH) is a
progressive disease of the lung vascular system, which leads
to right-sided heart failure and ultimately death if untreated.
Treatments to regulate the pulmonary vascular pressure
target the prostacyclin, nitric oxide, and endothelin (ET)
pathways. Macitentan, an oral, once-daily, dual ETA and
ETB receptor antagonist with high affinity and sustained
receptor binding is the first ET receptor antagonist to show
significant reduction of the risk of morbidity andmortality in
PAHpatients in a large-scale phase III studywith a long-term
outcome. Here we present a review of the available clinical
pharmacokinetic, pharmacodynamic, pharmacokinetic/
pharmacodynamic relationship, and drug–drug interaction
data of macitentan in healthy subjects, patients with PAH,
and in special populations.
Key Points
Macitentan is a novel dual endothelin receptor
antagonist.
Macitentan requires once-daily dosing (active
metabolite present) and has a low propensity to elicit
drug–drug interactions.
Macitentan is not a substrate of active drug transporters,
possibly leading to a better liver safety profile.
1 Introduction
Pulmonary arterial hypertension (PAH) is a chronic disease
characterized by an increase in pulmonary vascular resis-
tance, which leads to right ventricular failure and ulti-
mately death if not treated [1, 2]. PAH is a rare condition
affecting 15–50 people per million population. Discussion
of the classification, diagnosis, and assessment of PAH at
consensus meetings has resulted in recommendations that
were incorporated into international guidelines and were
recently updated during the 5th World Symposium on
Pulmonary Hypertension in 2013 in Nice, France [3, 4]. In
short, PAH is the first of five general categories of pul-
monary hypertension. It can be idiopathic or heritable, but
can also be the result of drug or toxin use or associated with
other diseases such as mixed connective tissue disease,
HIV infection, portal hypertension, congenital heart dis-
ease, schistosomiasis, and chronic hemolytic anemia [3–9].
The basis of the increase in pulmonary vascular resis-
tance resides in a combination of factors such as en-
dothelial dysfunction, increased contractility of small
pulmonary arteries, proliferation and remodeling of en-
dothelial and smooth muscle cells, and in situ thrombosis
[10–12].
The three identified mechanisms that are mainly in-
volved in regulation of the pulmonary vascular pressure are
the prostacyclin, nitric oxide (NO), and endothelin (ET)
pathways. Both the prostacyclin and the NO pathway act
directly on the vascular bed [11, 13].
ET-1, part of a family of closely related 21-amino-acid
polypeptides, works through a different mechanism pro-
moting endothelial dysfunction and vascular remodeling
[11]. ET-1 achieves its effects by activation of specific
G-protein-coupled cell surface receptors. Two subtypes of
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ET-1 have been identified, termed ETA and ETB receptors.
ETA receptors are predominantly located in vascular
smooth muscle cells and cardiomyocytes and mediate
contraction. ETB receptors are also present in smooth
muscle cells in which they have a similar function as ETA,
but are mainly located in vascular endothelial cells where
they mediate vascular dilatation through NO release and
regulate ET-1 uptake and production [14–21]. Under nor-
mal conditions, ET-1 production and clearance of ET-1
from the vascular bed is balanced, but in diseases such as
PAH, the balance is disrupted and leads to an increase in
circulating levels of ET-1 and detrimental effects [22–24].
It has been observed that in chronic pathological situations,
ETB receptors are down-regulated on endothelial cells and
up-regulated on smooth muscle cells and fibroblasts [25–
28]. While it could be hypothesized that the beneficial ef-
fects of ETB on the endothelial cells could be reduced by
blockade of ETB, selective ETA blockade would leave the
ETB receptors that are up-regulated on smooth muscle cells
functional. Specific blockade of ETA has been shown to
activate the renin–angiotensin system, potentially resulting
in edema [29, 30]. Therefore, sustained blockade of both
ET receptors may be a better strategy to obtain optimal
efficacy and safety [26, 28, 31–33].
ET receptor antagonists (ERAs) have been proven to be
effective in the treatment of PAH [34–38]. Treatment with
approved ERAs has been shown to confer improvements in
a number of important clinical endpoints, including exer-
cise capacity, modified New York Heart Association
(NYHA) functional class, and pulmonary hemodynamics
[34–38]. Both ETA/ETB receptor antagonists and selective
ETA receptor antagonists are currently licensed for the
treatment of PAH [39, 40]. Traditionally, approval was
granted based on short-term studies (12–16 weeks) with
low patient numbers, in which an improvement in exercise
capacity was shown, based on the distance walked in 6 min
[41, 42]. However, current guidelines for clinical research
on PAH encourage the conduct of long-term outcome
studies with morbidity/mortality endpoints [43–45]. Be-
sides ERAs, other specific pharmacotherapies such as
treatment with prostanoids, phosphodiesterase type-5
(PDE-5) inhibitors, or a stimulator of soluble guanylate
cyclase are used. Guidelines have recently been revised to
reflect current strategies with regard to targeted and com-
bination therapy [1, 36].
Macitentan (Fig. 1), N-[5-(4-Bromophenyl)-6-[2-[(5-bro-
mo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N0-propylsul-
famide, is an oral, once-daily, potent dual ETA/ETB receptor
antagonist.
Macitentan is metabolized to a major and pharmaco-
logically active metabolite, ACT-132577. In functional
assays, both macitentan and ACT-132577 behave as dual
receptor antagonists. ACT-132577 is approximately
fivefold less potent than macitentan on ETA receptors and
presents an ETA/ETB inhibitory potency ratio of 16, versus
50 for its parent compound [46]. Free median 50 % inhi-
bition concentration (IC50) values for ETA and ETB were
within the range of free concentrations observed in humans
treated with macitentan at the therapeutic dose of 10 mg,
suggesting that ETB blockade is achieved. In vivo, ET-1
plasma concentrations were increased, which is typical of
treatment with a dual ERA and not a selective ERA [46].
This sulfamide was the result of a targeted medicinal
chemistry program to identify a novel, potent ERAwith high
oral efficacy [47]. In preclinical models of hypertension and
PAH, macitentan showed a dose-dependent decrease in
mean arterial blood pressure without affecting the heart rate
[46, 47]. This decrease was even observed when macitentan
was given on top of the ERA bosentan, whereas this decrease
was not observed when bosentan was given on top of
macitentan [48]. Tissue targeting was achieved through an
increase in acid dissociation constant (pKa) and logD values
resulting in a higher affinity of macitentan for lipophilic
structures [46]. In vitro, macitentan displayed insurmount-
able antagonism to ET receptors, due to its slower apparent
receptor association rate when compared with other ERAs
[49]. Therefore, macitentan could lead to a more effective
blockage blockade of ET-1 than other ERAs [49].
Macitentan was granted approval for the treatment of
PAH in several countries including the USA, Canada,
Europe, and Switzerland and marketed as Opsumit at a
dosing regimen of 10 mg once daily [50–52] following the
results of SERAPHIN (Study with an Endothelin Receptor
Antagonist in Pulmonary Arterial Hypertension to Improve
Clinical Outcome), a landmark phase III study. SER-
APHIN was a long-term, randomized, placebo-controlled
study in PAH patients. The primary endpoint used was a
clearly defined morbidity/mortality endpoint allowing
evaluation of the efficacy and safety of macitentan [53, 54].
Two dose levels (3 and 10 mg) were studied; macitentan
reduced the risk of a morbidity/mortality event vs. placebo
(10 mg dose, risk reduction 45 %, p\ 0.001; 3 mg dose,
risk reduction 30 %, p = 0.01) and was well-tolerated at
both dose levels [53]. The number of adverse events (AEs)
reported and of patients discontinuing treatment due to AEs
was similar across all treatment groups and the incidence of
macitentan-induced liver injury was comparable to that
induced by placebo [53]. A thorough discussion of the
study and its limitations is provided by Pulido et al. [53] as
well as Dingemanse et al. [54].
2 Drug Formulations
In early clinical phase I and II studies, macitentan was
administered in hard gelatin capsules [55]. A film-coated
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tablet of macitentan 10 mg, which is easier to ingest than
the capsule, was developed for later phase I and III studies
and subsequently marketed as Opsumit. The in vitro
dissolution rate of a macitentan 10 mg capsule was slightly
higher than that of the tablet formulation, while dissolution
characteristics of an uncoated tablet formulation did not
differ from the coated formulation [55]. In healthy male
subjects, the extent of absorption of macitentan given as a
tablet was slightly lower than the capsule formulation,
leading to the lower of the 90 % confidence limits of the
geometric mean ratio for maximum plasma concentration
(Cmax) to fall outside the commonly referenced range of
bioequivalence of 0.80–1.25. Geometric mean ratios and
90 % confidence intervals (CIs) of total exposure expressed
as area under the plasma concentration–time curve (AUC)
from time zero to infinity (AUC?) and AUC from time
zero to last timepoint t of the measurable plasma concen-
trations (AUCt) were completely within the referenced
bioequivalence range [55]. As the change in Cmax observed
in the tablet formulation was minor and total exposure,
which is a more relevant measure for drugs that are used
long-term, was not different from that of the capsule for-
mulation, the observation was considered to be not
clinically relevant. Therefore, no dose adjustment was
needed for the tablet formulation.
3 Bioanalysis of Macitentan and Metabolites
In the course of its clinical development, in a dedicated
study investigating the absorption, distribution, metabo-
lism, and elimination (ADME) of macitentan, a pharma-
cologically inactive metabolite, ACT-373898, was
discovered [56]. As the inactive metabolite had been
characterized adequately in animals (see Sect. 4.3) and did
not appear in high enough concentrations to raise concern
in human studies [56], ACT-373898 was not routinely
measured in healthy subjects and only assessed in subjects
with hepatic and renal impairment.
Macitentan, its active metabolite ACT-132577, and its
pharmacologically inactive metabolite ACT-373898
(Fig. 1) were determined in human plasma using a
Fig. 1 Proposed metabolic pathways of macitentan in humans and animals
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validated liquid chromatography–tandem mass spec-
trometry (LC-MS/MS) method. After thawing, human
plasma samples were vortexed and centrifuged, and a
mixture of acetonitrile/ethanol was added followed by ad-
dition of the deuterated standard. After protein precipita-
tion, plasma samples were filtrated through a protein
precipitation plate and the filtrate was injected onto the
high-performance liquid chromatography (HPLC) column.
The analysis of macitentan and ACT-132577 was per-
formed by separation with reverse-phase chromatography
followed by detection with triple-stage quadrupole tandem
mass spectrometry (MS/MS) in positive ion mode. The
assay was linear in the concentration range 1–2000 ng/mL
for both analytes. The performance of the method was
monitored using quality control samples at concentrations
of 3, 100, and 1500 ng/mL [55, 57]. In the study with
renally impaired subjects, ACT-373898 was measured
separately and was detected using triple-state quadrupole
MS/MS in negative ion mode [57].
4 Pharmacokinetics in Healthy Adults
4.1 Absorption
4.1.1 Single-Dose Administration
The entry-into-human study was performed in healthy male
subjects with a single-center, double-blind, randomized,
placebo-controlled study design [58]. Doses of macitentan
0.2, 1, 5, 25, 100, 300, and 600 mg or placebo were in-
vestigated under fasted conditions in groups of eight sub-
jects (six on active, two on placebo) each. The
pharmacokinetic parameters after single-dose administra-
tion are shown in Table 1. After oral administration,
macitentan was slowly absorbed with median time to Cmax
(tmax) varying from 8 to 30 h for the different dose groups.
Thereafter, macitentan plasma concentrations decreased
slowly. The apparent elimination half-life (t) could only
be reliably estimated for the 300 and 600 mg dose groups
and was approximately 16 h. The Cmax of macitentan in-
creased less than dose proportionally as indicated by a
value for the dose-proportionality coefficient b of 0.83
(95 % CI 0.79–0.87) [58].
Formation of the pharmacologically active metabolite
ACT-1323577 was slow with Cmax values attained at the
earliest 30 h after dosing (Table 1). In comparison to the
parent compound, plasma concentrations of the metabolite
were higher and elimination was slower, as demonstrated
by mean t values varying from 40 to 66 h (Table 1). Total
exposure (AUC?) to the metabolite was 2.7-fold (95 % CI
2.5–2.9) greater than to macitentan at a dose of 600 mg
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10 mg was administered to healthy subjects showed similar
pharmacokinetic results [57].
4.1.2 Effect of Food on Absorption
The effect of food on the pharmacokinetics of single-dose
macitentan and ACT-132577 was investigated in healthy
subjects [59]. In an exploratory, open-label, randomized,
two-period, crossover study, subjects received macitentan
10 mg once under fasted conditions and, after a washout
period, once after consumption of a high-fat, high-calorie
breakfast as recommended in US FDA and European
Medicines Agency (EMA) guidelines [60, 61]. Exposure
to both macitentan and its active metabolite expressed in
Cmax and AUC was unchanged in the presence of food.
This was evidenced by the point estimates for Cmax and
AUC and their 90 % CIs falling entirely within the ref-
erenced bioequivalence range of 0.80–1.25 [99]. There-
fore, macitentan can be administered with and without
food [59, 62, 63].
4.1.3 Multiple-Dose Administration
The multiple-ascending dose study was performed in
healthy male subjects in a single-center, double-blind,
randomized, placebo-controlled study design [64]. Oral
doses of macitentan 1, 3, 10, and 30 mg or placebo, ad-
ministered once daily under fasted conditions for 10 days,
were investigated in groups of eight subjects (six on active,
two on placebo) each. Steady-state conditions for maci-
tentan and ACT-132577 were reached by days 3 and 7,
respectively [64]. The pharmacokinetic parameters after
multiple-dose administration are shown in Table 2. After
multiple-dose administration, macitentan reached Cmax at
approximately 8 h and was eliminated slowly as indicated
by its t varying from 14 to 19 h [64]. Accumulation was
limited when comparing AUC during a dosing interval
(AUCs) on day 10 with that of day 1 (Table 2). Both AUCs
and Cmax were dose-proportional over the dose range
tested.
Similar to the entry-into-human study, ACT-132577 was
slowly formed and eliminated with tmax and t values of 8
and 48 h, respectively (Table 2). Due to its slow formation
and slow elimination, ACT-132577 accumulated sig-
nificantly as indicated by an accumulation index of 7–10
for the different doses (Table 2) [64].
4.1.4 Absolute Bioavailability
No absolute bioavailability study has been performed.
However, oral bioavailability was estimated using Simcyp
Population-Based ADME Simulator. Using a physio-







































































































































































































































































































































































































































































































































































































































































































































































































































































































Clinical PK/PD of Macitentan 461
combined with genetic, physiological, and demographic
variables derived from population databases, an oral
bioavailability of 74 % was estimated for macitentan [65].
4.2 Distribution, Protein Binding, and Blood
Partitioning
Using Professional WinNonlin (Pharsight Corp.,
Mountain View, CA, USA) a one-compartment model
with a lag time and first-order input and elimination was
fit to describe the steady-state plasma concentration vs.
time data of macitentan and ACT-132577 after oral ad-
ministration. The model indicated an apparent oral vol-
ume of distribution at steady state (Vss/F) of
approximately 50 and 40 L for macitentan and ACT-
132577, respectively. Macitentan and ACT-132577 dis-
tributed well into tissues as indicated by Vss/F exceeding
volume of total body water [63].
Macitentan and its active metabolite are highly bound to
plasma proteins ([99 %), primarily to albumin and to a
smaller extent to a1-acid glycoprotein [56, 63].
In the ADME study, concentrations of total radioactivity
in plasma were greater than in whole blood [56]. The
blood/plasma ratio of the total radioactivity concentration
of 0.55 was close to the theoretical blood-to-plasma dis-
tribution ratio (l-hematocrit = 0.57), indicating that maci-
tentan and its metabolites poorly bind to or penetrate into
blood cells. This was also in accordance with in vitro data
on blood cell/plasma partitioning, which showed no no-
table uptake of either macitentan or ACT-132577 into
human erythrocytes [56].
4.3 Metabolism and Elimination
The disposition and metabolism of macitentan were in-
vestigated in a dedicated ADME study in which six male
subjects received a single oral dose of 14C-labeled maci-
tentan with a target radioactivity of 2.78 MBq (970 l
Sievert) [56].
Excretion of the radioactivity involved both renal and
fecal routes, with urine being the most important elimina-
tion route. In humans, there were three, four, and five en-
tities detected in plasma, urine, and feces, respectively
(Fig. 1). Besides macitentan and M6 (ACT-132577), a
pharmacologically inactive metabolite (M5, ACT-373898)
was observed in plasma. Macitentan is metabolized in
humans by four independent pathways: (1) oxidative de-
propylation of the sulfamide group to form the pharma-
cologically active metabolite M6; formation of M6 is
mainly catalyzed by cytochrome P450 (CYP) 3A4, with
minor contributions of CYP2C8, CYP2C9, and CYP2C19;
(2) oxidative cleavage of the ethylene glycol catalyzed by
CYP2C9 to form the alcohol M4, which is subsequently
oxidized to the corresponding acid M5 and then hydrolyzed
to m/z 324; (3) oxidative depropylation of one of the distal
carbon atoms to form M7, mainly catalyzed by CYP2C9,
with minor contributions of CYP2C8 and CYP2C19; and
(4) chemical hydrolysis of macitentan and ACT-132577 to
form M3 (ACT-080803). The most abundant entities in
urine and feces were M5 and M3, respectively. The
metabolites identified in humans had also been detected in
animal studies and the latter provided sufficient coverage
for the human situation (Fig. 1). Therefore, no unique hu-
man metabolite was identified in this study. In addition, no
metabolite structure was identified, which would be
indicative of a safety concern. Based on in vitro and in vivo
toxicology studies, there was no evidence of genotoxicity
with macitentan [56].
5 Pharmacokinetics in Special Populations
5.1 Pharmacokinetics in Healthy Asian Subjects
The pharmacokinetics of a drug could be influenced by
ethnicity due to intrinsic differences such as genetic poly-
morphisms in metabolic pathways, differences in dose–
response relationships, and differences in bioavailability,
but also due to extrinsic differences such as body compo-
sition and food habits [66]. Therefore, pharmacokinetic
studies were conducted to investigate the effect of ethnicity
on the pharmacokinetics of macitentan.
After single-dose administration of macitentan 10 mg to
ten healthy male and female Caucasian and ten healthy
male and female Japanese subjects, the geometric mean
ratio and its 90 % CI of Cmax of macitentan and ACT-
132577 fell entirely within the referenced bioequivalence
range of 0.80–1.25. The t was slightly shorter in Japanese
subjects, resulting in a 15 % decrease in AUC? [67]. As
this decrease in exposure was small and exposures were
within the ranges observed in other phase I studies, this
difference was considered to be of no clinical relevance
[67].
The pharmacokinetics of macitentan and ACT-132577
were further investigated in multiple-ascending dose stud-
ies in 30 healthy Korean subjects [68] and 24 Japanese
subjects [100]. Doses of macitentan 3, 10, and 30 mg or
placebo were studied in groups of ten Korean subjects
(eight on active, two on placebo) and eight Japanese sub-
jects (six on active, two on placebo) each. The pharma-
cokinetic results were similar to those observed in the
multiple-ascending dose study in Caucasians.
Overall, based on these studies, no dose adjustment
would be needed for subjects of different ethnicities [68].
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5.2 Effect of Sex and Age on Pharmacokinetics
The effect of sex and age on the pharmacokinetics of
macitentan and ACT-132577 was investigated in the con-
text of the study in healthy Japanese subjects, subjects with
renal and hepatic impairment, and pharmacokinetic
assessments of patients in phase II and III [57, 67, 69].
Results indicate that, in general, females show a small in-
crease in t of up to 22 %, leading to an increase in ex-
posure of up to 25 % to macitentan and ACT-132577. This
finding is likely to be caused by a difference in body size
and body fat between females and males [57, 67, 69]. Sub-
analysis of pharmacokinetic data of macitentan and ACT-
132577 from the SERAPHIN study showed no clear effect
of age (Actelion Pharmaceuticals Ltd, data on file). In
summary, as exposures were not or only marginally dif-
ferent and exposures were in line with population ranges,
no dose adjustment of macitentan for sex and age is re-
quired [62, 63].
5.3 Pharmacokinetics in Subjects with Hepatic
Impairment
The pharmacokinetics of macitentan, ACT-132577, and
ACT-373898 were studied after administration of a single
dose of macitentan 10 mg to subjects with mild, moderate,
and severe hepatic impairment due to liver cirrhosis in a
single-center, open-label design. Hepatic impairment was
determined according to Child-Pugh grade based on
screening laboratory test results for serum bilirubin, serum
albumin, prothrombin time, and the stage of hepatic en-
cephalopathy, with or without ascites. The study investi-
gated sequential groups of eight subjects with mild,
moderate, and severe hepatic impairment. A control group
of eight healthy subjects was matched to and studied to-
gether with the severe hepatically impaired subjects [57].
Plasma concentrations were generally lower in subjects
with hepatic impairment than in healthy subjects, which is
reflected in geometric mean ratios varying between 0.54
and 1.13 for Cmax and AUC? (Table 3). No correlation
between degree of hepatic impairment and pharmacoki-
netics could be discerned. In fact, subjects with severe
hepatic impairment were very similar to the matched
healthy subjects, as indicated by geometric mean ratios
varying between 0.74 and 1.03 for the different analytes
(Table 3) [57]. The unbound macitentan and ACT-132577
fraction in plasma was determined in all study groups and
ranged between 0.09–0.26 % and 0.52–1.09 %, respec-
tively. No pattern related to the level of hepatic impairment
in plasma protein binding of macitentan and ACT-132577
was detected. Levels of unbound ACT-373898 increased
with severity and were 2.39 ± 0.26 % (healthy subjects),
2.11 ± 0.52 % (mild hepatic impairment), 3.05 ± 0.71 %
(moderate hepatic impairment), and 3.97 ± 0.95 % (severe
hepatic impairment) [57].
No dose adjustments based on pharmacokinetics would
be needed. However, no clinical data are available in PAH
patients with moderate or severe hepatic impairment [63].
Macitentan, as have other ERAs, has been associated with
hepatotoxicity. Therefore, macitentan should not be initi-
ated in PAH patients with severe hepatic impairment [54,
63].
5.4 Pharmacokinetics in Subjects with Renal
Impairment
The pharmacokinetics of a single dose of macitentan
10 mg were investigated in eight subjects with severe renal
function impairment (SRFI) and eight healthy subjects
matched for age, sex, and weight, in a single-center, open-
label design. Subjects with SRFI were defined as having a
creatinine clearance of 15–29 mL/min using the Cockroft-
Gault formula. Healthy subjects had a creatinine clearance
[70 mL/min for subjects aged 50–60 years and[80 mL/
min for subjects\50 years [57].
The plasma concentration–time profiles of macitentan
and ACT-132577 were similar in healthy subjects and
those with SRFI. However, clearance of macitentan and
ACT-132577 was slower in subjects with SRFI as indicated
by a slightly longer t. This resulted in increases in ex-
posures demonstrated by a geometric mean ratio (90 % CI)
of 1.11 (0.80–1.54) and 1.24 (0.83–1.85) for Cmax and
AUC?, respectively, of macitentan and 1.39 (1.07–1.81)
and 1.58 (1.24–2.01) for Cmax and AUC?, respectively, of
ACT-132577, which were not considered clinically rele-
vant. As ACT-373898 is predominantly eliminated by the
kidneys, its exposure increased markedly in SRFI subjects
as indicated by a geometric mean ratio (90 % CI) of 4.24
(3.10–5.80) and 7.31 (5.42–9.86) for Cmax and AUC?,
respectively [57]. Due to the low concentrations of circu-
lating ACT-373898, its lack of activity on the ET receptor,
and sufficient margin established in toxicology studies, the
increase is not clinically relevant and does not necessitate
dose adjustment.
5.5 Pharmacokinetics in Patients with Essential
Hypertension
Trough plasma samples were collected at week 4 and 8 in a
multicenter, double-blind, randomized, placebo- and ac-
tive-controlled, dose-ranging study to evaluate the efficacy
and safety of macitentan in subjects with mild-to-moderate
essential hypertension. Dose levels that were investigated
were macitentan 0.3, 1, 3, and 10 mg once daily for up to
8 weeks [70]. Trough concentrations (Ctrough) were con-
sistent after week 4 and 8 of treatment. Pharmacokinetic
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analysis showed that exposure in terms of Ctrough of both
macitentan and ACT-132557 was dose proportional over
the dose range tested [70].
5.6 Pharmacokinetics in Patients with Pulmonary
Arterial Hypertension
In the pivotal phase III SERAPHIN study in patients with
PAH, plasma samples were taken at end of treatment
(EOT) in all 742 patients and at month 6 in 187 patients
participating in a sub-study [69]. Macitentan steady-state
Ctrough values ranged from below limit of quantification to
801 ng/mL. Arithmetic means (±standard deviation)
showed clear differences between the two doses (month 6:
92 ± 53 and 291 ± 155 ng/mL, for macitentan 3 and
10 mg, respectively; EOT: 76 ± 61 and 208 ± 139 ng/mL,
for macitentan 3 and 10 mg, respectively) [69]. A cross-
study comparison showed that Ctrough values of macitentan
and ACT-132577 were higher in patients with PAH than
in healthy subjects. However, differences in exposure in
terms of Cmax and AUC between PAH patients and healthy
subjects were minor. This was based on a pharmacokinetic
profile over 24 h at steady-state that was obtained from 20
patients treated with macitentan 10 mg in the open-label
extension study of SERAPHIN. Results indicated
that exposure to macitentan and ACT-132577 was 1.2- and
1.3-fold, respectively, greater in PAH patients than in
healthy subjects and was not influenced by the severity of
the disease [62, 63].
6 Pharmacodynamics
6.1 Pharmacodynamics in Healthy Subjects
6.1.1 ET-1 Concentrations in Healthy Subjects
In the single- and multiple-ascending dose studies, ET-1
concentrations were measured in plasma at regular inter-
vals using a commercially available radioimmunoassay
[58, 64]. In these studies ET-1 concentrations increased
with dose. Statistical significance compared with placebo
was observed at doses of 25 mg and up for single-dose
administration and 10 mg and up for multiple-dose ad-
ministration (Fig. 2). ET-1 concentrations did not sig-
nificantly increase at 30 mg compared with 10 mg of
macitentan given as multiple doses, suggesting that its
maximum had been reached. Based on these results, a
10 mg dose was selected for clinical development.
6.1.2 Effect on Cardiac Repolarization
The effect of macitentan on cardiac repolarization was
studied in a thorough corrected QT (QTc) interval (TQT)
study following regulatory guidance [71, 72]. The study
was performed as a double-blind, randomized, placebo-
and positive-controlled, four-way crossover study. Treat-
ment arms consisted of moxifloxacin 400 mg, macitentan
10 mg (therapeutic dose), macitentan 30 mg (supra-
therapeutic dose), and placebo for 9 days [73]. The upper
bound of the 90 % CI of the primary endpoint, which was
the baseline-adjusted, placebo-corrected QT interval using
the Fridericia correction method (DDQTcF), was below
10 ms at all timepoints, whereas moxifloxacin showed a
clear prolongation of QTcF. No correlation between
pharmacokinetic parameters and ECG variables and no
treatment-related morphological ECG abnormalities were
detected [73]. The data indicate that macitentan and ACT-
132577 do not affect the QTc interval and that, therefore,
no specific ECG monitoring is needed for clinical use.
6.1.3 Bile Salts
Serum bile salts were measured in the single- and multiple-
ascending dose studies at regular intervals using a com-
mercially available enzymatic assay [58, 64].
No significant differences between the macitentan and
placebo groups were detected, therefore suggesting that
macitentan does not interfere with hepatic bile salt trans-
port, unlike some other ERAs such as bosentan [58, 64,
74]. Hepatic disposition of macitentan is driven by passive
diffusion with no role of active uptake transporters such as
organic anion-transporting polypeptide (OATP). As maci-
tentan is highly bound to plasma proteins, hepatocellular
Table 3 Geometric mean ratios (90 % CI) of the Cmax and AUC? of macitentan and its metabolites when comparing subjects with varying
degrees of hepatic impairment with healthy subjects following a single oral dose of macitentan 10 mg
Mild hepatic impairment Moderate hepatic impairment Severe hepatic impairment
Cmax AUC? Cmax AUC? Cmax AUC?
Macitentan 0.77 (0.60–0.98) 0.79 (0.62–1.01) 0.52 (0.42–0.66) 0.66 (0.52–0.84) 0.81 (0.65–1.03) 0.94 (0.74–1.19)
ACT-132577 0.74 (0.57–0.97) 0.81 (0.61–1.06) 0.79 (0.61–1.02) 0.75 (0.57–0.98) 0.76 (0.59–0.99) 0.74 (0.57–0.97)
ACT-373898 1.13 (0.81–1.59) 1.13 (0.81–1.59) 0.64 (0.48–0.86) 0.65 (0.47–0.90) 0.96 (0.71–1.28) 1.03 (0.74–1.42)
AUC? area under the plasma concentration–time curve from time zero to infinity, Cmax maximum concentration
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drug concentrations are too low to inhibit transport proteins
involved in bile salt trafficking [75]. Indeed, macitentan
appears to have a favorable hepatic safety profile with liver
enzyme elevations similar to placebo, as observed in
clinical trials [54].
6.2 Pharmacodynamics in Patients
6.2.1 ET-1 Concentrations in Patients
ET-1 measured at trough in a study with patients with
essential hypertension showed a clear dose-related effect at
doses of macitentan 3 and 10 mg once daily (Actelion
Pharmaceuticals Ltd, data on file) [70].
6.3 Pharmacokinetic/Pharmacodynamic Relationships
Pharmacokinetic/pharmacodynamic analysis in PAH pa-
tients was performed to investigate possible relationships
between pharmacokinetics (trough samples collected at
EOT and month 6) and hemodynamic parameters, 6 min
walk distance (6MWD), laboratory parameters, and AEs
leading to study drug discontinuation [69]. Different ap-
proaches [linear, log linear, and maximum effect (Emax)
models] were assessed to establish the best fit. The results
indicated that the pharmacodynamic variables pulmonary
vascular resistance, mean pulmonary artery pressure, total
pulmonary resistance, and cardiac output correlated with
plasma concentration. No relationship was established be-
tween plasma concentrations and mean right arterial pres-
sure or mixed venous oxygen saturation [69]. No
correlations could be established between plasma concen-
trations and laboratory variables or the probability of AEs
leading to discontinuation [69].
7 Drug–Drug Interactions
7.1 Drug–Drug Interaction Potential
Weiss et al. investigated the interaction potential of maci-
tentan on critical drug-metabolizing enzymes and drug
transporters in vitro [76]. Macitentan was found to moder-
ately inhibit breast cancer resistance protein (BCRP),
CYP3A4, CYP2C19, and clearly inhibited P-glycoprotein
(P-gp) [76]. However, further in vitro and in vivo studies,
performed at clinically relevant concentrations, showed that
macitentan is not a substrate of P-gp [62]. Hepatic uptake is
mostly driven by passive diffusion and is not dependent on
OATP transport, unlike other ERAs such as bosentan [75, 77,
78]. Macitentan showed a potential to inhibit OATPB1 and
OATPB3; however, taking into consideration the high pro-
tein binding and low clinical drug concentrations, it is un-
likely that treatment with macitentan would affect the
pharmacokinetics of coadministered drugs dependent on
OATP transport [76, 78]. The limited drug interaction po-
tential of macitentan was demonstrated in a number of
in vivo drug–drug interaction studies summarized in the next
sections. The effects of other drugs on the pharmacokinetics
of macitentan and ACT-132577 are shown in Fig. 3.
7.2 Warfarin
Warfarin is an anticoagulant commonly administered to
patients with PAH [1, 4, 79, 80]. It consists of a racemic
mixture of R- and S-enantiomers. The elimination of war-
farin is almost entirely by metabolism, after which it is ex-
creted into the urine. Warfarin is metabolized by CYP
enzymes (CYP2C9, CYP2C19, CYP2C8, CYP2C18,
CYP1A2, and CYP3A4) to inactive hydroxylated
Fig. 2 Arithmetic mean (±standard deviation) plasma endothelin-1
concentrations in healthy subjects after single-dose (left panel) and
multiple-dose (right panel) administration of macitentan (n = 6 per
dose level) or placebo (n = 14 left panel, n = 8 right panel). AUCs
area under the concentration–time curve during a dosing interval,
AUC48 area under the concentration–time curve from time zero to
48 h, ET endothelin, *p\ 0.05 vs. placebo
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metabolites and by reductases to reduced metabolites with
minimal anticoagulation activity. The S-enantiomer is pri-
marily metabolized by CYP2C9, and less by CYP2C19 and
CYP3A4, whereas the R-enantiomer is mainly metabolized
by CYP1A2, with a smaller contribution of CYP3A4 [81].
As warfarin has a narrow therapeutic index, which requires
careful monitoring, it was important to investigate the po-
tential effect of macitentan on warfarin pharmacokinetics
and pharmacodynamics in a drug–drug interaction study. In
this study, 12 healthy male subjects were exposed to two
treatments: (A) a single dose of 25mg; and (B) a loading dose
of macitentan 30 mg on day 1 followed by 10 mg once daily
for 8 days, with a single 25 mg dose of warfarin on day 4 in a
randomized, open-label, single-center, two-way crossover
design [82]. A loading dose strategy was chosen to ensure
that steady-state conditions of macitentan and ACT-132577
would be attained earlier than day 7 (i.e., day 3). The phar-
macokinetic parameters tmax,Cmax, AUC?, and t of R- and
S-warfarin were studied. Pharmacodynamics were investi-
gated by determination of AUC from time zero to 144 h
(AUC144) and tmax of international normalized ratio (INR)
and factor VII activity [83].
The mean plasma concentration–time profiles of R- and
S-warfarin in the presence and absence of macitentan were
similar and geometric mean ratios and 90 % CI of Cmax and
AUC? fell entirely in the reference bioequivalence range
of 0.80–1.25. No effect of macitentan on INR and factor
VII activity was detected [82].
7.3 Sildenafil
Sildenafil, a PDE-5 inhibitor used for the treatment of
PAH, is metabolized predominantly via CYP3A4 (major
route) and CYP2C9 (minor route). The major circulating
active metabolite results from N-desmethylation of silde-
nafil and is, itself, further metabolized [84, 85]. To inves-
tigate the potential mutual interaction between macitentan
and sildenafil, 12 healthy male subjects received (A) a
loading dose of macitentan 30 mg on day 1 followed by
10 mg once daily for 3 days; (B) sildenafil 20 mg three
times a day for 3 days and a single 20 mg dose on day 4;
and (C) both treatments A and B concomitantly in an open-
label, randomized, three-way crossover study. On day 4 of
each treatment the pharmacokinetics of macitentan, ACT-
132577, sildenafil, and N-desmethylsildenafil were deter-
mined [86]. In the presence of sildenafil, macitentan
pharmacokinetics were not affected, as shown in Fig. 3.
Exposure to ACT-132577, on average, decreased by ap-
proximately 17 and 15 % for Cmax and AUCs, respectively,
which was not clinically relevant. In the presence of
macitentan, plasma concentrations of sildenafil were higher
than during treatment with sildenafil alone, resulting in
increased Cmax and AUCs values. The respective geometric
mean ratios (90 % CI) were 1.26 (1.07–1.48) and 1.15
(0.94–1.41). The pharmacokinetics of N-desmethylsilde-
nafil were not affected by macitentan [86].
7.4 Ketoconazole
Ketoconazole, a broad-spectrum antifungal agent, is a
strong inhibitor of CYP3A4 and was used as a sensitive
tool for assessing this effect on the pharmacokinetics of
macitentan [87, 88]. In a two-period, randomized, open-
label crossover study, ten healthy subjects received (A) a
single oral dose of macitentan 10 mg; and (B) ketocona-
zole 400 mg once daily for 4 days, coadministration of
Fig. 3 Effects of other drugs on macitentan and ACT-132577 pharmacokinetics. Black circle macitentan, Cross ACT-132577
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macitentan 10 mg with ketoconazole 400 mg on day 5,
followed by continued administration of ketoconazole
400 mg once daily for 19 additional days [89]. In the
presence of ketoconazole, exposure to macitentan in-
creased approximately twofold, while exposure to ACT-
132577 was reduced by 26 % (Fig. 3). As macitentan is
prescribed for long-term use, pharmacokinetic modeling
was performed to predict the interaction between keto-
conazole and macitentan under steady-state conditions.
Results of the modeling indicated that exposure to maci-
tentan in the presence of ketoconazole would be threefold
that without macitentan, which is an exposure well-toler-
ated in the multiple-ascending dose study [64]. Exposure to
ACT-132577 would be reduced by 25 % [89]. Results
indicate that macitentan, in principal, could be adminis-
tered together with strong CYP3A4 inhibitors as the in-
creased exposure is well-tolerated by subjects. However,
due to the lack of long-term safety data in subjects and
patients exposed to higher concentrations of macitentan,
caution should be exercised using concomitant treatment
with strong CYP3A4 inhibitors [62, 63].
7.5 Cyclosporine
Cyclosporine (ciclosporin), which is an inhibitor of OATP,
Pg-p, and BCRP as well as a weak inhibitor of CYP3A4, is
a co-medication used in PAH patients. Drug–drug inter-
actions between cyclosporine and other ERAs that are
substrates for OATP have been reported [90, 91]. The ef-
fect of cyclosporine on macitentan pharmacokinetics was
investigated in a single-center, open-label, one-sequence,
crossover study design [78, 92, 93]. Ten healthy subjects
received a loading dose of macitentan 30 mg on day 1
followed by macitentan 10 mg once daily for 17 days. On
days 6–17, subjects received concomitant cyclosporine
100 mg in a twice-daily dosing regimen. Based on dosing
recommendations for cyclosporine, both macitentan and
cyclosporine were administered after a meal. In the pres-
ence of cyclosporine, macitentan Ctrough values were in-
creased on average by 38 %; however, the increase in
exposure during a dosing interval was limited (i.e., 10 %)
(Fig. 3). In this study, the pharmacokinetics of ACT-
373898 were also studied, which were not affected by
concomitant cyclosporine [78]. The data indicate that
macitentan and its metabolites are not substrates of the
drug transporters OATP, P-gp, and BCRP. Overall, maci-
tentan can be used concomitantly with cyclosporine with
no need for dose adjustment.
7.6 Rifampin
Rifampin (rifampicin), an antibacterial mainly used for the
treatment of tuberculosis, is a strong inducer of CYP3A4
[87, 94]. In a single-center, open-label, one-sequence,
crossover study design ten healthy subjects received a
loading dose of macitentan 30 mg on day 1 followed by
macitentan 10 mg once daily for 12 days. On day 6, sub-
jects received concomitant rifampin 600 mg once daily
until day 12 [78]. Macitentan concentrations decreased
markedly, i.e., AUCs decreased by approximately 80 %
(Fig. 3). Daily exposure to ACT-132577 in the presence of
rifampin did not change (geometric mean ratio of 1.00;
90 % CI 0.89–1.12) [78]. Although ACT-132577 con-
tributes to the overall pharmacological effect, the ap-
proximately fourfold reduction in exposure to macitentan
in the presence of a strong CYP3A4 inducer could impact
the overall efficacy of macitentan. Therefore, concomitant
treatment should be avoided [62, 63, 78].
8 Discussion
Macitentan was approved at a dose of 10 mg after having
undergone one of the largest phase III studies conducted in
PAH and used a composite morbidity/mortality primary
endpoint, consisting of clinically highly relevant compo-
nents. The pharmacokinetics of macitentan can be char-
acterized by slow absorption of macitentan and slow
formation of ACT-132577 with t values of 16 and 48 h,
respectively, therefore justifying a once-daily dosing regi-
men. Formation of ACT-132577 was mainly catalyzed by
CYP3A4 with minor contributions of CYP2C8, CYP2C9,
and CYP2C19. Over the dose range tested in multiple-dose
regimens the pharmacokinetics of macitentan and ACT-
132577 were dose proportional and not influenced by
meals, sex, age, or ethnicity. Due to elimination both by
liver and kidney, no dose adjustment based on pharma-
cokinetics appeared necessary in patients with hepatic or
renal impairment. It is remarkable that the pharmacoki-
netics of macitentan were not influenced by hepatic im-
pairment, given the observation that macitentan is
extensively metabolized before being excreted and that
unchanged macitentan was not detected in urine. A possi-
ble explanation could be that the major metabolites iden-
tified in urine and feces are hydrolysis products and,
therefore, only in part dependent on metabolism in the
liver. Further, it is known that in hepatically impaired pa-
tients hepatic levels of CYP enzymes are diminished but
this does not result in a decrease of CYP activity [95]. In
fact, many patients with chronic liver disease (without
cirrhosis) can metabolize drugs at a normal rate [95–98]. A
third hypothesis could be that urine and/or feces samples
were not sufficiently stabilized to prevent hydrolysis of
macitentan and ACT-132577, therefore underestimating
the amount of unchanged macitentan and ACT-132577
excreted.
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It must be noted that no clinical data of PAH patients
with severe or moderate hepatic impairment are available.
As the class of ERAs is associated with hepatotoxicity,
macitentan should not be used in patients with severe
hepatic impairment.
The pharmacokinetic characteristics of macitentan and
ACT-132577 were consistent in healthy subjects and pa-
tients with essential hypertension or PAH. This allows
utilization of population pharmacokinetic and pharma-
cokinetic/pharmacodynamic analysis methods to predict
concentrations in other patient populations, in particular
children, for whom no data exist at this time. Also, the
observed data can be useful for assessing the potential for
other drug–drug interactions. At the approved clinical dose
of macitentan of 10 mg, its drug–drug interaction potential
is considered low. Macitentan pharmacokinetics were not
affected by commonly co-prescribed medications in PAH
patients such as warfarin and sildenafil. Unlike other ERAs
such a bosentan, macitentan and ACT-132577 are not
substrates of OATP and can be administered concomitantly
with cyclosporine without need for dose adjustment. The
results of the study with cyclosporine, which inhibits other
drug transporters besides OATP, indicate that the phar-
macokinetics of macitentan would not be affected by in-
hibitors of OATP, P-gp or BCRP. Concomitant treatment
with a strong inhibitor or inducer of CYP3A4 affected the
pharmacokinetics markedly. Therefore, this combination
should be avoided. Using the clinical data of the study with
sildenafil, a sensitive substrate of CYP3A4, it is unlikely
that macitentan would affect other CYP3A4 substrates in-
cluding new oral anticoagulants (e.g., rivoraxaban) or
hormonal contraceptives. These drugs are frequently used
by PAH patients and, therefore, an absence of such an
interaction would provide benefit to the patient. The use of
modeling could support the absence of drug–drug
interactions.
The potential of macitentan to have an improved liver
safety profile is supported by a lack of effect on concen-
trations of bile salts and demonstrated in the pharmacoki-
netic/pharmacodynamic analysis of the SERAPHIN study
in which no correlations between macitentan concentra-
tions and increases in ALT, AST, and c-glutamyl trans-
ferase were detected. ET-1 data in healthy subjects and
patients with essential hypertension supported a dose of
10 mg as being efficacious, which was confirmed by the
SERAPHIN results. Results of the TQT study indicated
that macitentan, both at the therapeutic dose of 10 mg and
at a supratherapeutic dose of 30 mg, does not have a pro-
arrhythmic potential. The safety of macitentan has been
reviewed and reported in several other publications [53, 54,
75]. In clinical studies, macitentan had a good safety and
tolerability profile. As with other ERAs, macitentan carries
a black box warning because of risk of embryo-fetal
toxicity and a decrease in hemoglobin. Also, due to an
assumed pharmacologic class effect, macitentan could have
an adverse effect on spermatogenesis.
Data from the long-term phase III SERAPHIN study
indicate a favorable profile with respect to liver enzyme
elevations and edema/fluid retention.
In conclusion, the studies discussed in this review sup-
port the use of macitentan as an efficacious and well-tol-
erated treatment for patients with PAH with possible
benefits compared with treatment with other registered
ERAs.
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